ExQor Technologies Inc
Biotech · Private
Non-radioactive nanoprobes for MRI imaging of TrkB (tropomyosin receptor kinase B) in Alzheimer's disease, comprising a clathrin-based nanocarrier with gadolinium contrast agent and BDNF ligand
exqor.com →- Grants
- $11M
- 16 awards
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- —
- No federal contracts on record
- Patents
- —
- No published records under this name
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓2014201620182020202220242026
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Health and Human Services · Phase I · Preventing and Reducing HAND by Using New BDNF Nanoprobes | $225,060 | |
| Federal grant | Department of Health and Human Services · Phase I · Preventing and Reducing HAND by Using New BDNF Nanoprobes | $214,457 | |
| Federal grant | Department of Health and Human Services · Phase I · New Targeted BDNF Nanoparticles for Treatment of Dopaminergic Neurodegeneration in METH Addiction and HAND | $225,000 | |
| Federal grant | Department of Health and Human Services · Phase II · New BDNF Nanoparticles for Early Treatment of Alzheimer's Disease | $224,798 | |
| Federal grant· 1 of 2 same day | Department of Health and Human Services · Phase II · Preventing and Reducing HAND by Using New BDNF Nanoprobes | $1,289,097 | |
| Federal grant· 2 of 2 same day | Department of Health and Human Services · Phase II · Preventing and Reducing HAND by Using New BDNF Nanoprobes | $539,377 | |
| Federal grant | Department of Health and Human Services · Phase II · New BDNF Nanoparticles for Early Treatment of Alzheimer's Disease | $749,693 | |
| Federal grant | Department of Health and Human Services · Phase II · New BDNF Nanoparticles for Early Treatment of Alzheimer's Disease | $749,493 | |
| Federal grant | Department of Health and Human Services · Phase II · Preventing and Reducing HAND by Using New BDNF Nanoprobes | $749,720 | |
| Federal grant | Department of Health and Human Services · Phase II · New BDNF Nanoparticles for Early Treatment of Alzheimer's Disease | $100,002 | |
| Federal grant | Department of Health and Human Services · Phase II · New targeted BDNF nanoparticles for treatment of METH addiction and neurotoxicity | $1,194,659 | |
| Federal grant | Department of Health and Human Services · Phase II · New targeted BDNF nanoparticles for treatment of METH addiction and neurotoxicity | $1,184,259 | |
| Federal grant | Department of Health and Human Services · Phase II · New BDNF Nanoparticles for Early Treatment of Alzheimer's Disease | $1,006,687 | |
| Federal grant | Department of Health and Human Services · Phase II · New BDNF Nanoparticles for Early Treatment of Alzheimer's Disease | $995,987 | |
| Federal grant | Department of Health and Human Services · Phase II · New BDNF Nanoparticles for Early Treatment of Alzheimer's Disease | $995,987 | |
| Federal grant | Department of Health and Human Services · Phase II · New Nanoprobes for MR Imaging of TrkB in Alzheimer's Disease | $499,588 |
Federal grant · SBIR/STTR
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 3145 | CARDIAC RSK3 INHIBITORS, LLC | — | — |
| 3146 | AJK BIOPHARMACEUTICAL LLC | — | — |
| 3147 | Kinetiq | — | — |
| 3148 | ExQor Technologies Inc | — | — |
| 3149 | Lung Biotechnology | — | — |
| 3150 | VIBE PHARMACEUTICALS LLC | — | — |
| 3151 | SYNBAL INC | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.